New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
OverviewChart

Quote Panel

Shape
Updated July 17, 2025
1W % 1M % 3M % 1Y %

Key Metrics

Shape

  • Market Cap

  • Shares Outstanding

  • Share in Float

  • Dividende

  • Earning Date

    No Data

  • Price Target

  • Average Volume

  • Beta

  • Range

  • Industry

  • Website

  • Sector

Fundamentals

Shape

Relative Strength

Shape

PYPD

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

Analyst rating

Last analyst upgrade/downgrade

Earnings GrowthShape

status-upYoY

Current

Estimates

Q2.23

arrow
arrow

N/A

-3.90
vs -18.32

Q3.23

arrow
arrow

N/A

-3.40
vs -14.41

Q4.23

arrow
arrow

N/A

-3.97
vs -9.61

Q1.24

arrow
arrow

N/A

-1.37
vs -8.41

Q2.24

arrow
arrow

N/A

-1.25
vs -3.90

Q3.24

arrow
arrow

N/A

-1.22
vs -3.40

Q4.24

arrow
arrow

N/A

NA
vs -3.97

Q1.25

arrow
arrow

N/A

-0.70
vs -1.37

Q2.25

arrow
arrow

N/A

-0.55
vs -1.25

Q3.25

arrow
arrow

N/A

-0.33
vs -1.22

Sales GrowthShape

status-upYoY

Current

Estimates

Q4.22

arrow
arrow

NA

NA  vs NA

Q1.23

arrow
arrow

NA

NA  vs NA

Q2.23

arrow
arrow

NA

NA  vs NA

Q3.23

arrow
arrow

NA

NA  vs NA

Q4.23

arrow
arrow

NA

NA  vs NA

Q1.24

arrow
arrow

NA

NA  vs NA

Q2.24

arrow
arrow

NA

NA  vs NA

Q3.24

arrow
arrow

NA

NA  vs NA

Q4.24

arrow
arrow

NA

NA  vs NA

Q1.25

arrow
arrow

NA

NA  vs NA

Return on EquityShape

status-upQoQ

Q2.23

arrow
arrow

-70%

-0.70
vs -0.53

Q3.23

arrow
arrow

-158%

-1.58
vs -0.70

Q4.23

arrow
arrow

+303%

3.03
vs -1.58

Q1.24

arrow
arrow

-90%

-0.90
vs 3.03

Q2.24

arrow
arrow

-393%

-3.93
vs -0.90

Q3.24

arrow
arrow

-360%

-3.60
vs -3.93

Q4.24

arrow
arrow

-111%

-1.11
vs -3.60

Q1.25

arrow
arrow

-9614%

-96.14
vs -1.11

Institutionnal OwnershipShape

status-upQoQ

Q3.21

arrow
arrow

19

19
vs 22

-14%

Q4.21

arrow
arrow

30

30
vs 19

58%

Q1.22

arrow
arrow

31

31
vs 30

3%

Q2.22

arrow
arrow

30

30
vs 31

-3%

Q3.22

arrow
arrow

21

21
vs 30

-30%

Q4.22

arrow
arrow

14

14
vs 21

-33%

Q1.23

arrow
arrow

10

10
vs 14

-29%

Q2.23

arrow
arrow

13

13
vs 10

30%

Earnings Growth

Latest News

PYPD

globenewswire.com

7 hours ago

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints
PYPD

globenewswire.com

8 hours ago

PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market
PYPD

globenewswire.com

8 hours ago

BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript
PYPD

globenewswire.com

9 hours ago

PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention
PYPD

globenewswire.com

9 hours ago

PESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention
PYPD

globenewswire.com

19 hours ago

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results